Philadelphia Mag

Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial

The Philly-based biotech company will begin human testing of EBT-101, a CRISPR-based gene editing construct developed at Temple’s Lewis Katz School of Medicine. According to Excision’s CEO, Daniel ...
Yahoo Finance

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today ...
Yahoo Finance

Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing

SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced ...
BioWorld

Excision adds a $60M funding to develop CRISPR-based therapies

Excision Biotherapeutics Inc.’s CEO is specific when he talks about his company’s therapies and what they may achieve: a functional cure. “When you treat someone and they become cancer free, you can’t ...